Dr. CHIU Wing Yan, Joanne
BSc (Canada), MSc (Canada), MBBS (HK), MRCP (UK), FHKAM (Medicine), FHKCP(Med Onc), PDipID(HK)
Dr. Joanne Chiu is a specialist in medical oncology. Dr. Chiu received post-graduate education in pharmacology in Canada, and returned to Hong Kong for her medical degree. After completing her specialist training in Queen Mary Hospital, Dr. Chiu pursued a fellowship program in the Drug Development Program at Princess Margaret Cancer Center in Toronto.
From 2014 to 2019, she served as the Deputy Medical Director at the Phase 1 Clinical Trials Center at the University of Hong Kong. She is currently Clinical Assistant Professor at the Department of Medicine at the University of Hong Kong and Gleneagles Hospital Hong Kong. She is the principle investigator of many Phase 1 to Phase 3 clinical trials in breast cancer, genitourinary cancer, and lung cancer.
Dr. Chiu has special interest in new drug development in breast cancer and immunotherapy. She has been invited to speak in many oversea symposiums, and to serve as advisor for regional oncology meetings. She is also committee members for professional organizations such as Hong Kong Breast Cancer Foundation, and Breast Oncology Group.
Dr Simon Tucker
Chief Virologist & Head of Clinical Development, COVIRIX Medical
Dr Simon Tucker is an internationally recognized virologist with decades of pharmaceutical R&D management experience.
He previously led teams at GD Searle (US) focused on new antivirals including influenza and HIV, where he was a member of the team responsible for the discovery of the HIV protease inhibitor, amprenavir.
He subsequently led the Gene Therapy Group at the University of Glasgow (UK), before joining Biota Pharmaceuticals, a world-leading antiviral developer and originators of the NA class of influenza antivirals, amongst other discoveries. As Vice President of Research at Biota he oversaw the research and IP protocols, managed the R&D strategy and execution, and was directly involved in multiple licensing deals, collaborative projects with major pharmaceutical companies and the discovery and progression of clinical candidates. He led the teams that discovered zanamivir (Relenza), the world’s first neuraminidase inhibitor for treatment of influenza, as well as the world’s first point of care diagnostic test for influenza A and B.
He also presided over the discovery and development of candidate drugs for the common cold (Vapendavir), RSV and hepatitis C. He is founder and former CEO at 360biolabs and is currently Chairman of Jumpstart-Fertility, an international biotech focused on drugs to address female infertility.
Simon is Chief Virologist & Head of Clinical Development of COVIRIX Medical.
Dr. Balaji (Baloo) Panchapakesan
professor, scientist, inventor, innovator, and compassionate leader
Dr. Balaji Panchapakesan is a professor, scientist, inventor, innovator, and compassionate leader. He was a professor of mechanical engineering in the United States. His research involves combining nanoscience with medicine. He has published over 100 articles in leading journals and conferences. In 2022, the US State Department awarded him the Fulbright Academic and Professional Excellence Award for his work on breast cancer.
His interests lie in cancer diagnostic devices, circulating tumor cells, and immunotherapy. He invented the nanotube-CTC-chip for capturing circulating tumor cells in cancer patients.
Baloo is a strategic equal partner of Go-AI in the commercialization of Nanobomb Plus.
Level 1, 237 East Boundary Road
Bentleigh East, Victoria, 3165
Australia
Email: contact@go-ai.com.au